How Do Therapy Manufacturers Envision the Future of Hubs?

Imagine a world where clinical trials move seamlessly from concept to completion, staffing shortages are a thing of the past and patient recruitment happens at a record speed. Join Marken’s patient centric solutions expert and our featured guest for a dynamic discussion on how customizable site augmentation programs are accelerating life-saving treatments to market faster through scalable, flexible decentralized strategies. Learn practical solutions for streamlining on-site, remote or hybrid trials by matching dedicated clinical research professionals to your site’s unique needs, relieving staff burdens and empowering your team to focus on what matters most – patient care.

Tasked with the delivery of two ultra-sensitive gene therapies to Japan – treatments targeting vision loss that required continuous -80°C temperature control and dry ice replenishment throughout an 80-hour transit – Marken activated a customized, precision-driven supply chain strategy. Navigating one of the world’s most complex regulatory landscapes for advanced therapies, success depended on flawless execution, specialized handling protocols, and seamless cross-functional collaboration. So how did Marken overcome these high-stakes challenges – ensuring the integrity of these transformative therapeutics while exceeding client expectations? Read the full case study to find out.

When a South Korean patient needed a life-changing gene therapy, Marken orchestrated an international distribution strategy under the strictest regulatory and temperature specifications. With precise temperature-control required at -80°C with dry ice, Marken’s teams navigated weekend scheduling, specialized package handling and final-mile complexities to ensure the vital treatment remained on schedule with white glove service from pick up to final mile delivery. Discover how Marken made it happen.

At Advanced Therapies Week 2025, Rohin Iyer, Senior Director of Global CGT Operations at Marken, sat down for an exclusive interview with Phacilitate, offering perspective on the transformative advancements, emerging challenges, and future directions shaping the advanced therapies landscape. In this compelling discussion, Rohin explores key trends, including the increasing approval rates of allogeneic and autologous therapies, the exponential growth in the cell and gene therapy sector, and the shift toward earlier use of these therapies due to their curative potential. He also shares valuable insights into the most significant challenges and opportunities facing the CGT industry in 2025 and beyond, including how Marken, UPS Healthcare Precision Logistics is navigating and contributing to the future of advanced therapies, and delivering innovative solutions designed to meet the evolving needs of the field.

Radiopharmaceuticals are transforming cancer treatment, but their short half-lives and radioactive properties demand flawless, time-critical logistics. Marken’s integrated one UPS network ensures secure, temperature-controlled and compliant delivery every time - accelerating access to these life-saving therapies.